The first session of the AcTrip (Actoverco Thyroid Insight Practice) conference series, organized by Actoverco Pharmaceutical Group, was held with the aim of reviewing the challenges of screening, diagnosis, treatment, and follow-up of hypothyroidism (underactive thyroid). The event brought together 300 distinguished physicians and leading endocrinologists.

Introduction of Yutid (Levothyroxine Sodium)

According to Actoverco’s Public Relations Department, the conference was organized by the company’s Endocrinology and Diabetes Division at Parsian Evin Hotel. During the event, Eutide (Levothyroxine Sodium)—a product of Alborz Zagros Pharmaceutical Company, a subsidiary of Actoverco—was introduced.

This medication, which has been available in the Iranian pharmaceutical market since July, is prescribed as a thyroid hormone replacement therapy for the treatment of hypothyroidism, the management of thyroid cancer, and other conditions requiring thyroid hormone regulation as determined by a physician.

Conference Overview

The AcTrip conference was structured into two parts:

Part One: Screening and Diagnosis

After an introduction to the event and a real hypothyroid patient case presentation by Dr. Atiyeh Amoozgar (Professor of Endocrinology and Metabolism at Shahid Beheshti University of Medical Sciences), the session continued with expert discussions:

• Professor Fereidoun Azizi, a distinguished endocrinologist and Head of the Endocrinology and Metabolism Research Institute at Shahid Beheshti University, provided key insights into the fundamentals of managing thyroid disorders.
• Dr. Saeed Kalbasi, endocrinologist and faculty member at Shahid Beheshti University, along with Dr. Seyed Hossein Samadani-Fard, endocrinologist and faculty member at Iran University of Medical Sciences, delivered lectures on the principles of hypothyroidism screening and diagnosis.

Part Two: Treatment Approaches

In the second session, the treatment of hypothyroidism was examined in a panel discussion featuring:

• Professor Fereidoun Azizi (Endocrinologist),
• Dr. Sasan Sharghi (Endocrinologist and Metabolism Specialist),
• Dr. Babak Sharif Kashani (Cardiologist and Faculty Member at Shahid Beheshti University of Medical Sciences),
• Dr. Seyed Vahid Yousefi (Endocrinologist and Metabolism Specialist).

Key Insights on Pharmaceutical Quality

At the beginning of the event, Dr. Elham Kazemi, Head of Actoverco’s Diabetes Division, welcomed the attendees and emphasized key factors affecting drug quality and effectiveness. She highlighted the importance of:

• Using high-quality raw materials,
• Ensuring optimal active ingredient concentration in the final product,
• Maintaining stability and solubility for long-term effectiveness,
• Passing rigorous In Vitro and In Vivo standard tests,
• Implementing standardized packaging and distribution,
• Establishing a strong pharmacovigilance system to monitor drug safety.

She noted that only 20% of pharmaceutical production lines in Iran hold GMP certification, underscoring Actoverco’s commitment to maintaining the highest manufacturing standards. As the largest private pharmaceutical manufacturer in the Middle East, Actoverco follows the GMP regulations of top global pharmaceutical companies such as Merck and KRKA across its production facilities.

Alborz Zagros: The Only OEB5-Certified Pharmaceutical Plant in Iran

Dr. Kazemi highlighted that Alborz Zagros Pharmaceutical Company is the only Iranian pharmaceutical factory compliant with the global OEB5 standard. The facility includes two GMP-certified production lines from Merck, specializing in high-risk (HAZARDOUS) raw materials used in treatments for multiple sclerosis (MS), organ transplants, and other serious conditions.

The latest product from this factory, Yutid (Levothyroxine Sodium) tablets, is now available in 50 mcg and 100 mcg doses, with plans to introduce additional strengths.

Actoverco’s Commitment to Thyroid Disease Management

Dr. Kazemi concluded by emphasizing Actoverco’s dedication to social responsibility and its commitment to improving thyroid disease management in Iran. To achieve this, the company has launched the AcTrip conference series, creating a platform for leading experts to enhance knowledge and treatment approaches for thyroid disorders across the country.